Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Twenty-seven breast cancer women without heart failure, underwent CMR imaging (3T-Achieva,
Philips) before and 3 times serially after 4-cycles of adjuvant DOX (60mg/m2). CMR assessed
left ventricular (LV) ejection fraction (EF), T1 mapping pre and post gadolinium and late
gadolinium enhancement imaging. Biomarkers were obtained before and 72 hours after each
DOX-cycle.
Phase:
N/A
Details
Lead Sponsor:
University of Campinas, Brazil
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo